MA41758A - Procédés de traitement de l'infertilité - Google Patents

Procédés de traitement de l'infertilité

Info

Publication number
MA41758A
MA41758A MA041758A MA41758A MA41758A MA 41758 A MA41758 A MA 41758A MA 041758 A MA041758 A MA 041758A MA 41758 A MA41758 A MA 41758A MA 41758 A MA41758 A MA 41758A
Authority
MA
Morocco
Prior art keywords
treatment methods
infertility treatment
ovarian stimulation
controlled ovarian
controlled
Prior art date
Application number
MA041758A
Other languages
English (en)
Other versions
MA41758B1 (fr
Inventor
Saez Joan Carlos Arce
Jane Ruman
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA41758A publication Critical patent/MA41758A/fr
Publication of MA41758B1 publication Critical patent/MA41758B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42Gynaecological or obstetrical instruments or methods
    • A61B17/425Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0604Whole embryos; Culture medium therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/0609Oocytes, oogonia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)

Abstract

La présente invention concerne une technologie de reproduction assistée améliorée utilisant de la ménotropine hautement purifiée (hp-hmg) pour stimuler le développement de follicules dans une stimulation ovarienne contrôlée, en particulier chez des femmes présentant un risque élevé de réponse ovarienne à une stimulation ovarienne contrôlée.
MA41758A 2015-02-26 2016-02-25 Procédés de traitement de l'infertilité MA41758B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562121113P 2015-02-26 2015-02-26
US201562121131P 2015-02-26 2015-02-26
EP15157661 2015-03-04
EP15185191 2015-09-15

Publications (2)

Publication Number Publication Date
MA41758A true MA41758A (fr) 2018-01-03
MA41758B1 MA41758B1 (fr) 2024-03-29

Family

ID=56787937

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41758A MA41758B1 (fr) 2015-02-26 2016-02-25 Procédés de traitement de l'infertilité

Country Status (25)

Country Link
US (4) US10413592B2 (fr)
EP (2) EP4289477A3 (fr)
JP (2) JP7163027B2 (fr)
KR (1) KR102618298B1 (fr)
CN (2) CN113769069A (fr)
AU (1) AU2016223496B2 (fr)
CA (1) CA2976032A1 (fr)
DK (1) DK3261661T3 (fr)
ES (1) ES2968102T3 (fr)
FI (1) FI3261661T3 (fr)
HK (1) HK1246655A1 (fr)
HR (1) HRP20240013T1 (fr)
HU (1) HUE064604T2 (fr)
LT (1) LT3261661T (fr)
MA (1) MA41758B1 (fr)
MD (1) MD3261661T2 (fr)
MX (1) MX2017010320A (fr)
PH (1) PH12017501493A1 (fr)
PL (1) PL3261661T3 (fr)
RS (1) RS65096B1 (fr)
RU (1) RU2723098C2 (fr)
SG (1) SG11201706693QA (fr)
SI (1) SI3261661T1 (fr)
WO (1) WO2016135221A1 (fr)
ZA (1) ZA201705489B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3261661T3 (pl) 2015-02-26 2024-03-25 Ferring B.V. Menotropina do leczenia niepłodności
IL272763B2 (en) 2017-09-01 2024-02-01 Ferring Bv The composition for controlled stimulation of the ovary
CN109602394B (zh) * 2018-12-12 2020-01-17 北京大学第三医院 评估受试者卵巢储备功能的***
CN110491505B (zh) * 2019-08-22 2021-06-01 北京大学第三医院(北京大学第三临床医学院) 预测受试者卵巢刺激过程中获得的***数量的***
EP3932419A1 (fr) * 2020-06-29 2022-01-05 Ferring B.V. Procédés de traitement de la stérilité
TW202210096A (zh) * 2020-05-29 2022-03-16 荷蘭商菲林公司 治療不育症之方法
EP4171612A1 (fr) * 2020-06-26 2023-05-03 Ferring B.V. Hp-hmg pour une utilisation dans le traitement de l'infertilité chez une patiente atteint d'un syndrome des ovaires polykystiques
KR102498267B1 (ko) 2021-01-13 2023-02-13 주식회사 아이웍스 마이크로버블 생성 혼합 수중 에어레이터 회전분사 조립체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725579A (en) 1985-02-21 1988-02-16 Serono Laboratories, Inc. Method of in vitro fertilization by a unique combination of gonadotropins
EP1169349B1 (fr) 1999-04-16 2007-03-28 Instituto Massone S.A. Procede de preparation des compositions de gonadotrophines
WO2003022303A2 (fr) 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. Utilisation de hcg et de lh in dans l'hyperstimulation ovarienne controlee
US20140235540A1 (en) 2008-05-20 2014-08-21 Norbert Gleicher Androgen and gonadotropin treatment in females
RU2466724C1 (ru) 2011-05-31 2012-11-20 Фатима Якубовна Богатырева Способ лечения больных бесплодием, обусловленным поликистозом яичников, яичникового генеза на фоне хронического и острого воспаления органов малого таза
US9404908B2 (en) * 2013-04-29 2016-08-02 The Board of Truestees of the Leland Stanford Junior University Non-invasive imaging to the blastocyst stage for the detection of human embryonic aneuploidy
PL3261661T3 (pl) 2015-02-26 2024-03-25 Ferring B.V. Menotropina do leczenia niepłodności

Also Published As

Publication number Publication date
HK1246655A1 (zh) 2018-09-14
US11679145B2 (en) 2023-06-20
HUE064604T2 (hu) 2024-04-28
US20240009278A1 (en) 2024-01-11
MD3261661T2 (ro) 2024-04-30
SI3261661T1 (sl) 2024-03-29
ES2968102T3 (es) 2024-05-07
CN113769069A (zh) 2021-12-10
PH12017501493A1 (en) 2018-01-29
RS65096B1 (sr) 2024-02-29
AU2016223496A1 (en) 2017-08-10
RU2017131129A3 (fr) 2019-07-17
MX2017010320A (es) 2018-01-23
CA2976032A1 (fr) 2016-09-01
HRP20240013T1 (hr) 2024-03-29
RU2017131129A (ru) 2019-03-28
JP2020203904A (ja) 2020-12-24
FI3261661T3 (fi) 2024-01-15
US11351228B2 (en) 2022-06-07
KR102618298B1 (ko) 2023-12-26
US20200093893A1 (en) 2020-03-26
PL3261661T3 (pl) 2024-03-25
CN107257690A (zh) 2017-10-17
US10413592B2 (en) 2019-09-17
DK3261661T3 (da) 2024-01-15
SG11201706693QA (en) 2017-09-28
EP4289477A3 (fr) 2024-02-21
RU2723098C2 (ru) 2020-06-08
KR20170123321A (ko) 2017-11-07
LT3261661T (lt) 2024-01-25
US20210093697A1 (en) 2021-04-01
WO2016135221A1 (fr) 2016-09-01
EP3261661B1 (fr) 2023-10-18
AU2016223496B2 (en) 2021-09-09
US20160250296A1 (en) 2016-09-01
JP7157108B2 (ja) 2022-10-19
MA41758B1 (fr) 2024-03-29
EP3261661A1 (fr) 2018-01-03
ZA201705489B (en) 2024-02-28
JP2018511575A (ja) 2018-04-26
EP4289477A2 (fr) 2023-12-13
JP7163027B2 (ja) 2022-10-31

Similar Documents

Publication Publication Date Title
MA41758A (fr) Procédés de traitement de l'infertilité
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
WO2016100261A3 (fr) Procédé de traitement du cancer avec cgamp ou cgasmp
TW201613636A (en) Methods of treating Alzheimer's Disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2021015783A (es) Metodos de tratamiento de enfermedades colestaticas.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA46548A (fr) Fsh pour le traitement de l'infertilité
EA201791845A1 (ru) Твердые формы менахинолов
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
WO2016042561A3 (fr) Freination du mir-132 pour le traitement de troubles lipidiques
MY202466A (en) Methods for treatment of polycystic kidney disease
MY194135A (en) Treatment and diagnosis of inflammatory disorders
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
MA50163A (fr) Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité
EA201890514A1 (ru) Соединение тетрагидрооксепинопиридина
MA41930A1 (fr) Composition pour traitement de la maladie du bayoud
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств
MA38411B1 (fr) Inhibiteurs de cdc7
UA95472U (uk) Спосіб лікування хворих на неалкогольну жирову хворобу печінки